Skip to main content

Advertisement

SpringerLink
Log in

Treatment Options for Surgically Resectable Gastric Cancer

  • Gastrointestinal Malignancies
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Surgery is the only curative therapy for gastric cancer. The standard recommendations for resectable gastric adenocarcinoma are free-margin surgery with at least D1 resection and the removal of a minimum of 15 lymph nodes. The overall 5-year survival rate for resected gastric patients remains poor due to locoregional recurrence. The results of a large North American study (Gastrointestinal Cancer Intergroup Trial INT 0116) reported that postoperative chemoradiotherapy conferred a survival advantage compared with surgery alone, which led to the regimen being adopted as a standard of care. More recently the MAGIC/UK Medical Research Council (MRC) trial demonstrated that perioperative chemotherapy resulted in an improvement in overall survival and progression free survival. Thus, two successful strategies are available to improve outcomes in patients with localized gastric cancer. This article reviews data on adjuvant and perioperative treatment modalities for gastric cancer. The article discusses ongoing randomized adjuvant and perioperative trials that are designed to optimize chemotherapy regimens and also investigate combinations of chemotherapy and biologic agents. It is important to understand the mechanisms or pathways involved in gastric cancer development and metastasis. Identification of novel molecules pivotal to tumor biology may lead to new therapeutic approaches for this malignancy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, has been highlighted as: • Of importance •• Of major importance

  1. Greenlee RT, Murray T, Bolden S, Wingo PA: Cancer statistics, 2000. CA Cancer J Clin 2000, 50:7–33.

    Article  CAS  PubMed  Google Scholar 

  2. Ajani JA: Chemotherapy for gastric carcinoma: new and old options. Oncology (Huntingt) 1998, 12(10 Suppl 7):44–47.

    CAS  Google Scholar 

  3. Gunderson LL: Gastric cancer: patterns of relapse after surgical resection. Semin Radiat Oncol 2002, 12:150–161.

    Article  PubMed  Google Scholar 

  4. Gunderson LL, Sosin H: Adenocarcinoma of the stomach: areas of failure in a re-operation series (second or symptomatic look) clinicopathologic correlation and implications for adjuvant therapy. Int J Radiat Oncol Biol Phys 1982, 8:1–11.

    CAS  PubMed  Google Scholar 

  5. Landry J, Tepper J, Wood W, et al.: Analysis of survival and local control following surgery for gastric cancer. Int J Radiat Oncol Biol Phys 1986, 12:119.

    Google Scholar 

  6. Landry J, Tepper J, Wood W, et al.: Patterns of failure following curative resection of gastric carcinoma. Int J Radiat Oncol Biol Phys 1990, 19:1357–1362.

    CAS  PubMed  Google Scholar 

  7. Bozzetti F, Marubini E, Bonfanti G, et al.: Subtotal versus total gastrectomy for gastric cancer: five-year survival rates in a multicenter randomized Italian trial. Ann Surg 1999, 230:170–178.

    Article  CAS  PubMed  Google Scholar 

  8. Viste A, Haugstvedt T, Eide GE, et al.: Postoperative complications and mortality after surgery for gastric cancer. Ann Surg 1988, 207:7–12.

    Article  CAS  PubMed  Google Scholar 

  9. Cuschieri A, Weeden S, Fielding J, et al.: Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Cooperative Group. Br J Cancer 1999, 79:1522–1530.

    Article  CAS  PubMed  Google Scholar 

  10. Hartgrink HH, van de Velde CJ, Putter H, et al.: Extended lymph node dissection for gastric cancer: Who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol 2004, 22:2069–2077.

    Article  CAS  PubMed  Google Scholar 

  11. McCulloch P, Nita ME, Kazi H, et al.: Extended versus limited lymph node dissection technique for adenocarcinoma of the stomach. Cochrane Database Syst Rev 2003, CD001964

  12. Wolff A, Davidson N: Primary systemic therapy in operable breast cancer. J Clin Oncol 2000, 18:1558–1569.

    CAS  PubMed  Google Scholar 

  13. Ajani JA, Ota DM, Jessup JM: Resectable gastric carcinoma: an evaluation of preoperative and postoperative chemotherapy. Cancer 1991, 68:1501–1506.

    Article  CAS  PubMed  Google Scholar 

  14. Ajani JA, Mayer RJ, Ota DM: Preoperative and postoperative combination chemotherapy for potentially resectable gastric carcinoma. J Natl Cancer Inst 1993, 85:1839–1844.

    Article  CAS  PubMed  Google Scholar 

  15. Ajani JA, Mansfield PF, Lynch PM: Enhanced staging and all chemotherapy preoperatively in patients with potentially resectable gastric carcinoma. J Clin Oncol 1999, 17:2403–2411.

    CAS  PubMed  Google Scholar 

  16. Hartgrink HH, van de Velde CJH, Putter H, et al.: Neo-adjuvant chemotherapy for operable gastric cancer; long-term results of the Dutch randomised FAMTX trial. Eur J Surg Oncol 2004, 30:643–649.

    Article  CAS  PubMed  Google Scholar 

  17. Boige V, Pignon J, Saint-Aubert B, et al.: Final results of a randomized trial comparing perioperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial. Proc Am Soc Clin Oncol 2007, 25:18s (abstract 4510).

    Google Scholar 

  18. Zhang Z-X, Gu X-Z, Yin W-B, et al. Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of adenocarcinoma of the gastric cardia (AGC): report on 370 patients. Int J Radiat Oncol Biol Phys. 1998; 42:929-934.

    CAS  PubMed  Google Scholar 

  19. Fiorica F, Cartei F, Enea M, et al.: The impact of radiotherapy on survival in resectable gastric carcinoma: a meta-analysis of literature data. Cancer Treat Rev 2007, 33:729–740.

    Article  PubMed  Google Scholar 

  20. Ajani JA, Mansfield P, Janjan N, et al.: Multiinstitutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J Clin Oncol 2004, 22:2774–2780.

    Article  CAS  PubMed  Google Scholar 

  21. Ajani JA, Mansfield PF, Crane CH, et al.: Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: Degree of pathologic response and not clinical parameters dictated patient outcome. J Clin Oncol 2005, 23:1237–1244.

    Article  CAS  PubMed  Google Scholar 

  22. Cunningham D, Allum WH, Stenning SP, et al.: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006, 355:11–20.

    Article  CAS  PubMed  Google Scholar 

  23. Roth AD, et al.: Comparative evaluation in tolerance of neoadjuvant versus adjuvant docetaxel based chemotherapy in resectable gastric cancer in a randomized trial of the Swiss Group for Clinical Cancer Res (SAKK) and the European Institute of Oncology (EIO). World Congress of Gastrointestinal Cancers Barcelona, Spain, 2007

  24. Earle C, Maroun J: Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials. Eur J Cancer 1999, 35(7):1059–1064.

    Article  CAS  PubMed  Google Scholar 

  25. Mari E, Floriani I, Tinazzi A, et al.: Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell’Apparato Digerente). Ann Oncol 2000, 11(7):837–843.

    Article  CAS  PubMed  Google Scholar 

  26. Sakuramoto S, Sasako M, Yamaguchi T, et al.: Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007, 357:1810–1820.

    Article  CAS  PubMed  Google Scholar 

  27. Chu QS, Hammond LA, Schwartz G, et al.: Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once daily-for-28-day schedule in patients with advanced malignancies. Clin Cancer Res 2004, 10(15):4913–4921.

    Article  CAS  PubMed  Google Scholar 

  28. Nakajima M, Fukami T, Yamanaka H, et al.: Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations. Clin Pharmacol Ther 2006, 80:282–297.

    Article  CAS  PubMed  Google Scholar 

  29. Fujita K, Yamamoto W, Endo H, et al.: Effects of CYP2A6 genotype and plasma level of 5-chloro-2,4-dihydroxipyridine (CDHP) on pharmacokinetics (PK) of tegafur (FT) and 5-fluorouracil (5-FU) in the patients treated by S-1. ASCO Meeting Abstracts 2007, 25:2504.

    Google Scholar 

  30. Macdonald JS, Smalley SR, Benedetti J, et al.: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001, 345:725–730.

    Article  CAS  PubMed  Google Scholar 

  31. Wagner AD, Grothe W, Haerting J, et al.: Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006, 24:2903–2909.

    Article  CAS  PubMed  Google Scholar 

  32. Van Cutsem E, Kang Y, Chung H, et al.: Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). Annual Meeting of ASCO 2009; abstract #LBA4509

  33. Yano T, Doi T, Ohtsu A, Boku N, Hashizume K, Nakanishi M, et al.: Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncol Rep 2006, 15:65–71.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Jack D. Weiler Hospital of The Albert Einstein College of Medicine, Montefiore Medical Center, 1825 Eastchester Road Rm# 2S-50, Bronx, NY, 10461, USA

    Lakshmi Rajdev MD, MS

Authors
  1. Lakshmi Rajdev MD, MS
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lakshmi Rajdev MD, MS.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rajdev, L. Treatment Options for Surgically Resectable Gastric Cancer. Curr. Treat. Options in Oncol. 11, 14–23 (2010). https://doi.org/10.1007/s11864-010-0117-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-010-0117-1

Keywords

Search

Navigation